Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RSV mRNA vaccine (modRNA-LNP)
- Development stage
- Approved
- Lead developer
- BioNTech
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
RSV mRNA vaccine (modRNA-LNP) refers to a class of prophylactic vaccines designed to prevent respiratory syncytial virus (RSV) infection using nucleoside-modified messenger RNA (modRNA) encapsulated in lipid nanoparticles (LNPs). The vaccine works by delivering modRNA encoding the RSV fusion (F) protein, typically stabilized in its prefusion conformation (preF), into host cells. Once inside the cells, the host machinery translates the mRNA into the preF antigen, which is then presented to the immune system to elicit robust neutralizing antibody and T-cell responses. This platform is utilized by multiple developers, including Moderna (with its approved vaccine mRESVIA/mRNA-1345) and Pfizer (which has evaluated prototype modRNA-LNP formulations in preclinical studies).
- Brand names
- mRESVIA
- Other names
- modRNA-LNP RSV vaccinenucleoside-modified mRNA RSV vaccineRSV modRNA-LNP vaccineRSV mRNA vaccine
02
Targets
HTM (Host translation machinery)RSV F (Respiratory syncytial virus fusion protein)
Beyond the preview
Go deeper on RSV mRNA vaccine (modRNA-LNP).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RSV mRNA vaccine (modRNA-LNP).